Why Halozyme Therapeutics, Inc.’s (HALO) Stock Is Up 6.38%
As of Wednesday, October 14, Halozyme Therapeutics, Inc.’s HALO share price has surged by 6.38%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Commentary & Analysis
Which Is a Better Investment, Halozyme Therapeutics, Inc. or BeOne Medicines AG Stock?
Learn more about whether Halozyme Therapeutics, Inc. or BeOne Medicines AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Why Halozyme Therapeutics, Inc.’s (HALO) Stock Is Up 5.05%
As of Monday, August 17, Halozyme Therapeutics, Inc.’s HALO share price has surged by 5.05%, which has investors questioning if this is right time to sell.Michael Rose
Which Is a Better Investment, Halozyme Therapeutics, Inc. or BeOne Medicines AG Stock?
Learn more about whether Halozyme Therapeutics, Inc. or BeOne Medicines AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, AbbVie Inc. or Halozyme Therapeutics, Inc. Stock?
Learn more about whether AbbVie Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | HALO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $14,258.8 | $229.7 | 83% |
|
| Shares Out (Mil) | 121.2 | 53.4 | 66% |
|
| Institutional Ownership | 99.1% | 92.9% | 85% |
|
| Float (Mil) | 112.2 | 41.7 | 63% |
|
| Beta | 0.88 | 0.95 | 52% |
|
| Avg Daily Volume (000s) | 2,414 | 520 | 84% |
|
| Price Change (52-week) |
91.0% | 46.5% | 94% |
|
| Growth | HALO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 39.2% | 13.2% | 93% |
|
| Net Income (5yr) | 19.7% | (10.1%) | 73% |
|
| EPS (5yr) | 23.0% | 15.8% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (3.2%) | (15.7%) | 62% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 5 | |
| Current EPS | $2.351 | $8.837 | $10.679 | |
| Month Ago EPS | $2.291 | $8.577 | $10.393 | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $2.167 | $8.112 | $9.985 | |
| Year/Year Chg | 23.7% | 245.2% | 372.1% | |
| Financials | HALO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,664 | $37 | 57% |
|
| Net Income (TTM) (Mil) | $414 | ($44) | 76% |
|
| EPS (TTM) | $3.518 | ($1.600) | 81% |
|
| Operating Cash Flow (TTM) (Mil) | $819 | ($33) | 78% |
|
| Net Cash Flow (TTM) (Mil) | $102 | $2 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $1,970 | $4 | 74% |
|
| Enterprise Value (Q1) (Mil) | $14,454 | $175 | 79% |
|
| Valuation | HALO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 99.71 | 2.17 | 99% |
|
| P/E | 37.1 | 20.1 | 78% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.6 | 1.1 | 63% |
|
| Ratios | HALO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.3% | 66.5% | 86% |
|
| Net Margin | 24.9% | (75.9%) | 83% |
|
| ROA | 17.9% | (47.2%) | 95% |
|
| ROE | 173.7% | (53.5%) | 98% |
|
| Liabilities to Assets | 94.4% | 29.4% | 92% |
|
| F-Score | 5 | 2 | 50% |
|
Passing Stock Screens
As of 10/23/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.3% |
| +/- S&P 500: | +13.8 |
FACTOR STRATEGY
P/E Relative Screen
Factors: Value, Earnings Estimates
A screen that looks at the relationship of a stock's price-earnings ratio to that of the industry and market.
| Performance Since Inception: | 13.4% |
| +/- S&P 500: | +5.9 |
